MA32442B1 - Inhibiteurs de la syk protéine kinase - Google Patents

Inhibiteurs de la syk protéine kinase

Info

Publication number
MA32442B1
MA32442B1 MA33302A MA33302A MA32442B1 MA 32442 B1 MA32442 B1 MA 32442B1 MA 33302 A MA33302 A MA 33302A MA 33302 A MA33302 A MA 33302A MA 32442 B1 MA32442 B1 MA 32442B1
Authority
MA
Morocco
Prior art keywords
methods
inhibitors
syk
protein kinase
inhibiting
Prior art date
Application number
MA33302A
Other languages
Arabic (ar)
English (en)
Inventor
Zhaozhong J Jia
Chandrasekar Venkataramani
Wolin Huang
Mukund Mehrotra
Yonghong Song
Qing Xu
Shawn M Bauer
Anjali Pandey
Brian Kane
Jack W Rose
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MA32442B1 publication Critical patent/MA32442B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés représentés par les formules i-v et des tautomères de ceux-ci, ou des sels pharmaceutiquement acceptables, des esters et des promédicaments de ceux-ci qui constituent des inhibiteurs de la syk kinase. L'invention concerne aussi des produits intermédiaires utilisés dans la fabrication de tels composés, la préparation d'un tel composé, des compositions pharmaceutiques contenant un tel composé, des procédés d'inhibition de l'activité de la syk kinase, des procédés d'inhibition de l'agrégation plaquettaire et des procédés destinés à prévenir ou à traiter des états pathologiques dus au moins en partie à l'activité de la syk kinase, tels qu'une thrombose indésirable et un lymphome malin non hodgkinien.
MA33302A 2008-04-16 2010-11-01 Inhibiteurs de la syk protéine kinase MA32442B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4549908P 2008-04-16 2008-04-16
US4540608P 2008-04-16 2008-04-16
US12034808P 2008-12-05 2008-12-05
US12034608P 2008-12-05 2008-12-05
PCT/US2009/002401 WO2009136995A2 (fr) 2008-04-16 2009-04-16 Inhibiteurs de la syk protéine kinase

Publications (1)

Publication Number Publication Date
MA32442B1 true MA32442B1 (fr) 2011-07-03

Family

ID=40793266

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33302A MA32442B1 (fr) 2008-04-16 2010-11-01 Inhibiteurs de la syk protéine kinase

Country Status (13)

Country Link
EP (1) EP2323993B1 (fr)
JP (2) JP5802127B2 (fr)
KR (3) KR20100132550A (fr)
CN (2) CN102066339B (fr)
CA (1) CA2728893C (fr)
CR (1) CR11793A (fr)
DO (1) DOP2010000309A (fr)
MA (1) MA32442B1 (fr)
MX (1) MX315135B (fr)
SG (2) SG165655A1 (fr)
SV (1) SV2010003705A (fr)
VN (1) VN29259A1 (fr)
WO (1) WO2009136995A2 (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164330A1 (fr) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Molécules d'anticorps anti-psyk et leur utilisation pour la thérapie ciblée sur syk
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
ES2433109T3 (es) * 2009-01-13 2013-12-09 Glaxo Group Limited Derivados de pirimidin-carboxamida como inhibidores de la Syk cinasa
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
CA2760061C (fr) * 2009-05-08 2017-02-28 Astellas Pharma Inc. Compose de carboxamide heterocyclique diamino
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
AU2010333804B2 (en) 2009-12-23 2015-07-16 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
PL2589592T3 (pl) 2010-06-30 2019-03-29 Fujifilm Corporation Nowe pochodne nikotynamidu lub ich sole
MY160734A (en) 2010-08-10 2017-03-15 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
KR20130108318A (ko) 2010-08-27 2013-10-02 메르크 파텐트 게엠베하 푸로피리딘 유도체들
KR20130110163A (ko) 2010-08-27 2013-10-08 메르크 파텐트 게엠베하 트리아졸로피라진 유도체들
JP2014005206A (ja) * 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物
NZ710636A (en) 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
US20130317029A1 (en) * 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
AU2011323484B2 (en) 2010-11-01 2016-10-06 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
WO2012061303A1 (fr) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Composés hétéroaryle et leurs utilisations
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
AU2012245387C1 (en) 2011-04-22 2016-05-05 Signal Pharmaceuticals, Llc Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
AU2016244228B2 (en) * 2011-04-22 2019-02-21 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
WO2012154518A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines en tant qu'inhibiteurs de syk
EP2706853B1 (fr) 2011-05-10 2017-06-14 Merck Sharp & Dohme Corp. Aminopyrimidines en tant qu'inhibiteurs de syk
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのピリジルアミノピリジン
WO2012177714A1 (fr) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Dérivés de 6-aza-isoindolin-1-one substitués
WO2013052391A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
EP2763976B1 (fr) * 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
CA2853498A1 (fr) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methodes de traitement d'une maladie ou d'une affection associee a la tyrosine-kinase btk (bruton's tyrosine kinase)
WO2013066729A1 (fr) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine
CA2856306A1 (fr) * 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Inhibiteurs selectifs de kinases
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
RU2576623C2 (ru) 2011-12-28 2016-03-10 Фуджифилм Корпорэйшн Новое производное никотинамида или его соль
WO2013104573A1 (fr) * 2012-01-10 2013-07-18 F. Hoffmann-La Roche Ag Composés de pyridazinamide et leur utilisation en tant qu'inhibiteurs de syk
TWI532727B (zh) * 2012-01-17 2016-05-11 安斯泰來製藥股份有限公司 吡羧醯胺化合物
US20150038527A1 (en) 2012-02-21 2015-02-05 Merck Patent Gmbh Furopyridine derivatives
ES2674451T3 (es) 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
UY34807A (es) * 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
WO2013192128A1 (fr) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
US20140113931A1 (en) * 2012-06-22 2014-04-24 Portola Pharmaceuticals, Inc. Substituted picolinamide kinase inhibitors
EP2863916B1 (fr) 2012-06-22 2018-07-18 Merck Sharp & Dohme Corp. Inhibiteurs à pyridine substituée de la tyrosine kinase de la rate (syk)
US9040530B2 (en) * 2012-06-22 2015-05-26 Portola Pharmaceuticals, Inc. 1,2,4-triazine-6-carboxamide kinase inhibitors
WO2013192088A1 (fr) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
EP2882746B1 (fr) 2012-08-07 2016-12-07 Merck Patent GmbH Dérivés de pyridopyrimidine en tant qu'inhibiteurs de protéine kinase
WO2014031438A2 (fr) 2012-08-20 2014-02-27 Merck Sharp & Dohme Corp. Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
EP2897950A1 (fr) 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)aminopyrimidino-5-carboxamides utilisés comme inhibiteurs de la spleen tyrosine kinase (syk)
EP2900665B1 (fr) 2012-09-28 2018-01-03 Merck Sharp & Dohme Corp. Dérivés triazolyle en tant qu'inhibiteurs de la syk
RU2641916C2 (ru) 2012-10-02 2018-01-23 Байер Кропсайенс Аг Гетероциклические соединения в качестве пестицидов
WO2014060371A1 (fr) * 2012-10-19 2014-04-24 F. Hoffmann-La Roche Ag Inhibiteurs de syk
SG11201503395TA (en) * 2012-11-08 2015-05-28 Bristol Myers Squibb Co ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2934525B1 (fr) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Aminopyridines substituées par thiazole en tant qu'inhibiteurs de la tyrosine kinase de la rate
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
WO2014152768A1 (fr) * 2013-03-15 2014-09-25 Portola Pharmaceuticals, Inc. Composés de cyclohexanediamine et leurs procédés de préparation
JP2016113366A (ja) * 2013-03-29 2016-06-23 大鵬薬品工業株式会社 アセトアミド基を有する１，２，４−トリアジン−６−カルボキサミド誘導体
EP2988749B1 (fr) 2013-04-26 2019-08-14 Merck Sharp & Dohme Corp. Aminopyrimidines substituées par thiazole utilisées en tant qu'inhibiteurs de tyrosine kinase splénique
EP2988744A4 (fr) 2013-04-26 2016-11-02 Merck Sharp & Dohme Composés aminohétéroaryle à substitution thiazole inhibiteurs de tyrosine kinase splénique
US9556148B2 (en) 2013-08-07 2017-01-31 Cadila Healthcare Limited N-cyanomethylamides as inhibitors of janus kinase
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
WO2015039613A1 (fr) * 2013-09-18 2015-03-26 北京韩美药品有限公司 Composé inhibant les activités kinase de btk et/ou jak3
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
WO2015094997A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
EP3083559B1 (fr) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Composés aminohétéroaryles à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
EP3116506B1 (fr) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. Composés 2-pyrazine carboxamide utiles comme inhibiteurs de la tyrosine kinase splénique
WO2016020403A1 (fr) * 2014-08-04 2016-02-11 Sandoz Ag Préparation d'un dérivé d'acide benzoïque et son utilisation pour la préparation de suvorexant
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
ES2877642T3 (es) 2014-12-16 2021-11-17 Signal Pharm Llc Formulaciones de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
WO2016100308A1 (fr) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Procédés de mesure de l'inhibition de la kinase à terminaison n c-jun dans la peau
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3795553B1 (fr) 2015-07-24 2024-05-15 Celgene Corporation Procédés de synthèse de chlorhydrate de (1r,2r,5r)-5-amino-2-méthylcyclohexanol et intermédiaires utiles à cet effet
ES2913119T3 (es) * 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
KR102571679B1 (ko) * 2016-04-15 2023-08-29 에피자임, 인코포레이티드 Ehmt1 및 ehmt2 저해제로서의 아민-치환된 아릴 또는 헤테로아릴 화합물
WO2018108704A1 (fr) * 2016-12-13 2018-06-21 Boehringer Ingelheim International Gmbh Nouveaux composés 6-amino-quinolinone et dérivés en tant qu'inhibiteurs de bcl6
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
CN109384774B (zh) * 2017-08-11 2023-02-17 中国科学院上海药物研究所 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用
CA3079292A1 (fr) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Utilisation de pyrrolidones heteroaromatiques fusionnees pour le traitement et la prevention de maladies chez des animaux
US10683297B2 (en) * 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
KR20210018193A (ko) * 2018-03-09 2021-02-17 포톨라 파마슈티컬스, 인코포레이티드 선택적 syk 억제자의 사용 방법 및 약학적 조성물
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
EP3797108B1 (fr) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulateurs de l'enzyme méthyl modifiant, compositions et leur utilisation.
DK3870579T3 (da) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibitorer og anvendelser deraf
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
MD4003532T2 (ro) 2019-07-24 2025-01-31 Constellation Pharmaceuticals Inc Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă
CA3159348A1 (fr) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes pour le traitement de cancers qui ont acquis une resistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US20230090742A1 (en) * 2020-01-30 2023-03-23 Sumitomo Pharma Oncology, Inc. Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
TW202227418A (zh) * 2020-10-12 2022-07-16 大陸商四川海思科製藥有限公司 一種雜環衍生物及其在醫藥上的應用
WO2022098809A1 (fr) * 2020-11-09 2022-05-12 Merck Sharp & Dohme Corp. Inhibiteurs de diaminopyrimidine carboxamide de hpk1
TW202246233A (zh) 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
TW202246232A (zh) * 2021-02-19 2022-12-01 英商蘇多生物科學有限公司 Ｔｙｋ２抑制劑及其用途
WO2022175745A1 (fr) * 2021-02-19 2022-08-25 Sudo Biosciences Limited Inhibiteurs de tyk2 et leurs utilisations
EP4294806A1 (fr) * 2021-02-19 2023-12-27 Sudo Biosciences Limited Inhibiteurs de tyk2 et leurs utilisations
CA3224094A1 (fr) * 2021-03-09 2022-09-15 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Utilisation d'un compose contenant un heteroaryle tricyclique
CN115197196B (zh) * 2021-04-06 2024-06-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
WO2023108536A1 (fr) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Inhibiteurs de tyk2 et compositions et procédés associés
AU2022412835A1 (en) * 2021-12-16 2024-06-20 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
CN116120282B (zh) * 2022-08-04 2024-02-20 苏州系统医学研究所 具有ev71和/或cva16病毒抑制活性的化合物及其应用
CN116925053A (zh) * 2023-07-26 2023-10-24 成都赜灵生物医药科技有限公司 甲磺酸普依司他中间体的杂质去除工艺
CN118440052B (zh) * 2024-07-05 2024-10-11 四川大学 一种化合物及其在制备tyk2激酶抑制剂中的用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839735D1 (de) * 1997-12-15 2008-08-28 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6797706B1 (en) * 1999-06-09 2004-09-28 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclecarboxamide derivative
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ATE430742T1 (de) 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
EP1434774A1 (fr) * 2001-10-10 2004-07-07 Sugen, Inc. Derives de 3- 4-(substitue heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone utiles comme inhibiteurs des kinases
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7459455B2 (en) 2002-02-08 2008-12-02 Smithkline Beecham Corporation Pyrimidine compounds
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
EP1515955A4 (fr) 2002-06-17 2006-05-03 Smithkline Beecham Corp Processus chimique
JP4529685B2 (ja) * 2002-06-28 2010-08-25 アステラス製薬株式会社 ジアミノピリミジンカルボキサミド誘導体
HRP20050089B1 (hr) * 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
JP4886511B2 (ja) * 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
BR122019017579B8 (pt) 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
WO2005122294A1 (fr) 2004-06-14 2005-12-22 Nec Corporation Dispositif électrique enveloppé dans une pellicule
AU2005281736A1 (en) * 2004-09-10 2006-03-16 Altana Pharma Ag Roflumilast and syk inhibitor combination and methods of use thereof
US20080027034A1 (en) * 2004-09-10 2008-01-31 Shah Tushar P Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
WO2008009458A1 (fr) * 2006-07-21 2008-01-24 Novartis Ag Composés de 2,4-di(arylamino)-pyrimidine-5-carboxamide comme inhibiteurs des jak kinases
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
EP2321283B1 (fr) * 2008-04-16 2016-07-13 Portola Pharmaceuticals, Inc. 2, 6-diamino-pyrimidin- b-yl-carboxamides servant d'inhibiteurs de syk kinases et de janus kinases

Also Published As

Publication number Publication date
EP2323993A2 (fr) 2011-05-25
CA2728893A1 (fr) 2009-11-12
CN102066339A (zh) 2011-05-18
KR20100132550A (ko) 2010-12-17
WO2009136995A3 (fr) 2009-12-30
KR20170051521A (ko) 2017-05-11
CN102066339B (zh) 2014-09-24
CN104230911A (zh) 2014-12-24
WO2009136995A2 (fr) 2009-11-12
CA2728893C (fr) 2017-03-14
SV2010003705A (es) 2011-03-23
JP2011518157A (ja) 2011-06-23
SG2014015085A (en) 2014-06-27
VN29259A1 (en) 2012-04-25
SG165655A1 (en) 2010-11-29
KR101773313B1 (ko) 2017-08-31
JP2015091806A (ja) 2015-05-14
KR20160088433A (ko) 2016-07-25
DOP2010000309A (es) 2011-03-15
JP5802127B2 (ja) 2015-10-28
MX315135B (en) 2013-11-07
CR11793A (es) 2011-03-07
EP2323993B1 (fr) 2015-06-03

Similar Documents

Publication Publication Date Title
MA32442B1 (fr) Inhibiteurs de la syk protéine kinase
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201001618A1 (ru) Ингибиторы syk протеинкиназ
EP4219465A3 (fr) Inhibiteurs de prmt5 et leurs utilisations
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MA32280B1 (fr) 2, 6-diamino-pyrimidin- b-yl-carboxamides servant d'inhibiteurs de syk kinases et de janus kinases
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
MX2007015863A (es) Inhibidores de esfingosina cinasa.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
WO2014153100A3 (fr) Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
TN2012000129A1 (en) SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
BR112013016595A2 (pt) inibidores de neprilisina
WO2009144555A8 (fr) Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
WO2014153235A3 (fr) Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MX339570B (es) Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
WO2011058474A8 (fr) Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
TN2011000585A1 (en) Lxr modulators